China Life Insurance, the world’s largest life insurer by market value, recorded an 81.5% increase in revenue to 434.3 billion yuan in the first half of 2026, alongside a 228% rise in net profit, driven by strategic investments in emerging technology fields including artificial intelligence, semiconductors, and biotechnology.
- First-half revenue surged 81.5% to 434.3 billion yuan
- Net profit jumped 228% to 134.5 billion yuan
- Plans to increase investments in AI, semiconductors, healthcare and biotech
What happened
China Life Insurance, listed in Shanghai and Hong Kong, released its interim financial report showing substantial year-on-year increases. Revenue reached 434.3 billion yuan (approximately $64.6 billion), up 81.5%, while net profit soared to 134.5 billion yuan, a 228% rise compared to the prior year. This performance marks record highs for the insurer.
The company attributed this growth to a combination of strong risk management, diversified product offerings, refined asset allocation, and favorable investment returns. Premiums from new policies also increased, reflecting ongoing demand and market confidence. The board declared an interim cash dividend significantly higher than the previous year.
Why it matters
China Life’s ramped-up investments demonstrate a clear strategic shift toward technology-driven sectors with long-term growth potential. Its portfolio includes companies like ChangXin Memory Technologies, showing a focus on semiconductors and emerging tech industries. The insurer views investments in artificial intelligence, healthcare, biotechnology, and new infrastructure as critical drivers for future returns.
By positioning itself as a long-term partner for innovative enterprises, China Life aims to diversify business risks and tap into China’s growing high-tech economy. The integration of AI technologies into its operational processes also points to enhanced efficiency and modernization in traditional insurance business models.
What to watch next
Market participants should monitor China Life’s expanding commitments in sectors such as AI and biotech to assess the impact on its investment portfolio and profit sources. The company’s performance will serve as a barometer for how traditional financial services firms in China adapt to and capitalize on emerging tech trends.
Future developments around new policy issuance growth and dividend payouts will also provide insights into the insurer’s balance of growth and shareholder returns. China Life’s ability to sustain momentum amid evolving market dynamics in both insurance and technology spaces will be critical.